PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

Haidong Tang, Yong Liang, Robert A. Anders, Janis M. Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M. Harrington, Jingya Guo, Yangchun Xin, Yahong Xiong, Kien Nham, William Silvers, Guiyang Hao, Xiankai Sun, Mingyi Chen, Raquibul Hannan, Jian Qiao, Haidong M Dong, Hua PengYang Xin Fu

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Programmed death–ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1–negative patients also respond to this therapy. In the current study, we explored whether PD-L1 on tumor or host cells was essential for anti–PD-L1–mediated therapy in 2 different murine tumor models. Using real-time imaging in whole tumor tissues, we found that anti–PD-L1 Ab accumulates in tumor tissues, regardless of the status of PD-L1 expression on tumor cells. We further observed that, while PD-L1 on tumor cells was largely dispensable for the response to checkpoint blockade, PD-L1 in host myeloid cells was essential for this response. Additionally, PD-L1 signaling in defined antigen-presenting cells (APCs) negatively regulated and inhibited T cell activation. PD-L1 blockade inside tumors was not sufficient to mediate regression, as limiting T cell trafficking reduced the efficacy of the blockade. Together, these findings demonstrate that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy.

Original languageEnglish (US)
Pages (from-to)580-588
Number of pages9
JournalJournal of Clinical Investigation
Volume128
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Neoplasms
Antigen-Presenting Cells
T-Lymphocytes
Therapeutics
Myeloid Cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., ... Fu, Y. X. (2018). PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation, 128(2), 580-588. https://doi.org/10.1172/JCI96061

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. / Tang, Haidong; Liang, Yong; Anders, Robert A.; Taube, Janis M.; Qiu, Xiangyan; Mulgaonkar, Aditi; Liu, Xin; Harrington, Susan M.; Guo, Jingya; Xin, Yangchun; Xiong, Yahong; Nham, Kien; Silvers, William; Hao, Guiyang; Sun, Xiankai; Chen, Mingyi; Hannan, Raquibul; Qiao, Jian; Dong, Haidong M; Peng, Hua; Fu, Yang Xin.

In: Journal of Clinical Investigation, Vol. 128, No. 2, 01.02.2018, p. 580-588.

Research output: Contribution to journalArticle

Tang, H, Liang, Y, Anders, RA, Taube, JM, Qiu, X, Mulgaonkar, A, Liu, X, Harrington, SM, Guo, J, Xin, Y, Xiong, Y, Nham, K, Silvers, W, Hao, G, Sun, X, Chen, M, Hannan, R, Qiao, J, Dong, HM, Peng, H & Fu, YX 2018, 'PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression', Journal of Clinical Investigation, vol. 128, no. 2, pp. 580-588. https://doi.org/10.1172/JCI96061
Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A et al. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation. 2018 Feb 1;128(2):580-588. https://doi.org/10.1172/JCI96061
Tang, Haidong ; Liang, Yong ; Anders, Robert A. ; Taube, Janis M. ; Qiu, Xiangyan ; Mulgaonkar, Aditi ; Liu, Xin ; Harrington, Susan M. ; Guo, Jingya ; Xin, Yangchun ; Xiong, Yahong ; Nham, Kien ; Silvers, William ; Hao, Guiyang ; Sun, Xiankai ; Chen, Mingyi ; Hannan, Raquibul ; Qiao, Jian ; Dong, Haidong M ; Peng, Hua ; Fu, Yang Xin. / PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 2. pp. 580-588.
@article{751b6437ae1843ef92ca95ba42a84308,
title = "PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression",
abstract = "Programmed death–ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1–negative patients also respond to this therapy. In the current study, we explored whether PD-L1 on tumor or host cells was essential for anti–PD-L1–mediated therapy in 2 different murine tumor models. Using real-time imaging in whole tumor tissues, we found that anti–PD-L1 Ab accumulates in tumor tissues, regardless of the status of PD-L1 expression on tumor cells. We further observed that, while PD-L1 on tumor cells was largely dispensable for the response to checkpoint blockade, PD-L1 in host myeloid cells was essential for this response. Additionally, PD-L1 signaling in defined antigen-presenting cells (APCs) negatively regulated and inhibited T cell activation. PD-L1 blockade inside tumors was not sufficient to mediate regression, as limiting T cell trafficking reduced the efficacy of the blockade. Together, these findings demonstrate that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy.",
author = "Haidong Tang and Yong Liang and Anders, {Robert A.} and Taube, {Janis M.} and Xiangyan Qiu and Aditi Mulgaonkar and Xin Liu and Harrington, {Susan M.} and Jingya Guo and Yangchun Xin and Yahong Xiong and Kien Nham and William Silvers and Guiyang Hao and Xiankai Sun and Mingyi Chen and Raquibul Hannan and Jian Qiao and Dong, {Haidong M} and Hua Peng and Fu, {Yang Xin}",
year = "2018",
month = "2",
day = "1",
doi = "10.1172/JCI96061",
language = "English (US)",
volume = "128",
pages = "580--588",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

AU - Tang, Haidong

AU - Liang, Yong

AU - Anders, Robert A.

AU - Taube, Janis M.

AU - Qiu, Xiangyan

AU - Mulgaonkar, Aditi

AU - Liu, Xin

AU - Harrington, Susan M.

AU - Guo, Jingya

AU - Xin, Yangchun

AU - Xiong, Yahong

AU - Nham, Kien

AU - Silvers, William

AU - Hao, Guiyang

AU - Sun, Xiankai

AU - Chen, Mingyi

AU - Hannan, Raquibul

AU - Qiao, Jian

AU - Dong, Haidong M

AU - Peng, Hua

AU - Fu, Yang Xin

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Programmed death–ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1–negative patients also respond to this therapy. In the current study, we explored whether PD-L1 on tumor or host cells was essential for anti–PD-L1–mediated therapy in 2 different murine tumor models. Using real-time imaging in whole tumor tissues, we found that anti–PD-L1 Ab accumulates in tumor tissues, regardless of the status of PD-L1 expression on tumor cells. We further observed that, while PD-L1 on tumor cells was largely dispensable for the response to checkpoint blockade, PD-L1 in host myeloid cells was essential for this response. Additionally, PD-L1 signaling in defined antigen-presenting cells (APCs) negatively regulated and inhibited T cell activation. PD-L1 blockade inside tumors was not sufficient to mediate regression, as limiting T cell trafficking reduced the efficacy of the blockade. Together, these findings demonstrate that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy.

AB - Programmed death–ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1–negative patients also respond to this therapy. In the current study, we explored whether PD-L1 on tumor or host cells was essential for anti–PD-L1–mediated therapy in 2 different murine tumor models. Using real-time imaging in whole tumor tissues, we found that anti–PD-L1 Ab accumulates in tumor tissues, regardless of the status of PD-L1 expression on tumor cells. We further observed that, while PD-L1 on tumor cells was largely dispensable for the response to checkpoint blockade, PD-L1 in host myeloid cells was essential for this response. Additionally, PD-L1 signaling in defined antigen-presenting cells (APCs) negatively regulated and inhibited T cell activation. PD-L1 blockade inside tumors was not sufficient to mediate regression, as limiting T cell trafficking reduced the efficacy of the blockade. Together, these findings demonstrate that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy.

UR - http://www.scopus.com/inward/record.url?scp=85041490670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041490670&partnerID=8YFLogxK

U2 - 10.1172/JCI96061

DO - 10.1172/JCI96061

M3 - Article

C2 - 29337303

AN - SCOPUS:85041490670

VL - 128

SP - 580

EP - 588

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -